We provide a system that analyzes medical images using AI and outputs musculoskeletal data.
Some children suffer from learning disabilities and experience difficulties in daily life due to poor eye movement, which makes it difficult to read and to play sports. We are developing an evidence-based system that uses eye tracking and eye movement indexing technologies to assess eye movements and provide training for children who are encountering these eyesight challenges. We are currently deploying this system in municipal consultation centers, elementary schools, and after-school day care centers.
We are conducting clinical development of an oral therapeutic cancer vaccine. We have completed a Phase I clinical trial targeting urothelial carcinoma and are currently conducting a Phase I/IIa clinical trial for malignant pleural mesothelioma.
Development and sales of solutions for preventing the worsening of diabetes complications.
CarbGeM is driving innovation in the life sciences through cutting-edge technologies, including regulatory-approved Software as a Medical Device (SaMD). The company empowers diagnostic support, research efficiency, and the standardization and automation of quality control. While addressing social challenges such as a shortage of skilled professionals and regional healthcare disparities, CarbGeM supports medical and industrial sectors by providing accurate and rapid results. Leveraging AI and digital platforms, the company fosters collaboration among healthcare professionals and researchers worldwide. CarbGeM is actively engaged in co-creating the future of medicine and science through open innovation with leading institutions across industry, academia, and government. The company has received numerous honors, including the Tokyo Social Innovation Tech Award 2024.
